DK420385A - Antioestrogent laegemiddel til perkutan indgift - Google Patents

Antioestrogent laegemiddel til perkutan indgift Download PDF

Info

Publication number: DK420385A
Authority: DK; Denmark
Prior art keywords: pct; percutive; antioestrogent; administration; medicine
Prior art date: 1984-01-20

Application number

DK420385A

Other languages

English (en)

Other versions

DK155143C (da

DK155143B (da

DK420385D0 (da

Inventor

Pierre Mauvais-Jarvis

Frederique Kuttenn

Original Assignee

Mauvais Jarvis Pierre

Frederique Kuttenn

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-01-20

Filing date

1985-09-17

Publication date

1985-09-17

1985-09-17 Application filed by Mauvais Jarvis Pierre, Frederique Kuttenn filed Critical Mauvais Jarvis Pierre

1985-09-17 Publication of DK420385A publication Critical patent/DK420385A/da

1985-09-17 Publication of DK420385D0 publication Critical patent/DK420385D0/da

1989-02-20 Publication of DK155143B publication Critical patent/DK155143B/da

1989-07-03 Application granted granted Critical

1989-07-03 Publication of DK155143C publication Critical patent/DK155143C/da

Links

RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 2
210000000481 breast Anatomy 0.000 abstract 2
229940046836 anti-estrogen Drugs 0.000 abstract 1
230000001833 anti-estrogenic effect Effects 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
239000000328 estrogen antagonist Substances 0.000 abstract 1
-1 p-dimethylaminoethoxyphenyl Chemical group 0.000 abstract 1
229960003387 progesterone Drugs 0.000 abstract 1
239000000186 progesterone Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Inorganic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Steroid Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DK420385A 1984-01-20 1985-09-17 Antioestrogent laegemiddel til behandling af benigne og canceroese tilstande i brystet DK155143C (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
FR8400927		1984-01-20
FR8400927A FR2558373B1 (fr)	1984-01-20	1984-01-20	Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
PCT/EP1984/000436 WO1985003228A1 (fr)	1984-01-20	1984-12-21	Medicament antioestrogene pour administration percutanee
EP8400436		1984-12-21

Publications (4)

Publication Number	Publication Date
DK420385A true DK420385A (da)	1985-09-17
DK420385D0 DK420385D0 (da)	1985-09-17
DK155143B DK155143B (da)	1989-02-20
DK155143C DK155143C (da)	1989-07-03

Family

ID=9300348

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK420385A DK155143C (da)	1984-01-20	1985-09-17	Antioestrogent laegemiddel til behandling af benigne og canceroese tilstande i brystet

Country Status (8)

Country	Link
US (1)	US4919937A (da)
EP (2)	EP0151326B1 (da)
JP (1)	JPH0667826B2 (da)
AT (1)	ATE73334T1 (da)
DE (1)	DE3485581D1 (da)
DK (1)	DK155143C (da)
FR (1)	FR2558373B1 (da)
WO (1)	WO1985003228A1 (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8604528D0 (en) *	1986-02-24	1986-04-03	Ici Plc	Therapeutic agents
ZA901847B (en) *	1989-03-10	1991-10-30	Endorecherche Inc	Combination therapy for the treatment of estrogen sensitive diseases
US5119827A (en) *	1990-09-05	1992-06-09	Board Of Regents, The University Of Texas System	Mechanisms of antiestrogen resistance in breast cancer
US5705185A (en) *	1991-09-25	1998-01-06	Beta Pharmaceuticals Co.	Transdermal delivery of estradiol and process for manufacturing said device
US5518734A (en) *	1991-09-25	1996-05-21	Beta Pharmaceuticals Co.	Transdermal delivery system for estradiol and process for manufacturing said device
GB9207437D0 (en) *	1992-04-03	1992-05-20	Orion Yhtymae Oy	Topical administration of toremifene and its metabolites
US5543150A (en) *	1993-09-15	1996-08-06	Columbia Laboratories, Inc.	Method of progesterone delivery and affect thereof
DE4407742C1 (de) *	1994-03-08	1995-06-22	Hexal Pharma Gmbh	Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
ES2156361T5 (es) †	1996-03-29	2012-12-26	Keyvest Gmbh	Cosmético o bien composición cosmética para el alisado y la tersura de la piel en el caso de tejido adiposo afectado, en especial en el caso de la "celulitis"
RU2123838C1 (ru) *	1996-07-31	1998-12-27	Акционерное общество открытого типа "Нижфарм"	Состав для лечения гирсутизма
US20020086856A1 (en)	1998-03-18	2002-07-04	Alfred Schmidt	Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor
EP0943333A1 (de) *	1998-03-18	1999-09-22	S.W. Patentverwertungs GmbH	Medikament zur Prophylaxe und/oder Behandlung des Mammakarzinoms enthaltend einen Hemmer der Bildung von Oestrogenen
FI982733L (fi)	1998-12-17	2000-06-18	Orion Yhtymae Oyj	Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia
US8119138B2 (en) *	2000-05-10	2012-02-21	Signe Biopharma Inc.	Anti-estrogen and immune modulator combinations for treating breast cancer
US7863011B2 (en) *	2000-05-10	2011-01-04	Signe Biopharma, Inc.	Screening method for predicting susceptibility to breast cancer
MXPA02011092A (es)	2000-05-10	2004-08-19	David A Sirbasku	Composiciones y metodos para demostrar la regulacion del sistema inmune secretor del crecimiento de la celula de cancer que responde a la hormona esteroidea.
US6503894B1 (en) *	2000-08-30	2003-01-07	Unimed Pharmaceuticals, Inc.	Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) *	2000-08-30	2004-05-13	Dudley Robert E.	Method of increasing testosterone and related steroid concentrations in women
DE10054294A1 (de) *	2000-11-02	2002-05-16	Heinrich Wieland	Topische Behandlung bei der Mastalgie
WO2003041654A2 (en) *	2001-11-14	2003-05-22	Sirbasku David A	Anti-estrogen and immune modulator combinations for treating breast cancer
JP2005513080A (ja)	2001-12-20	2005-05-12	フェムファーマ，インコーポレイテッド	薬物の膣送達
JP4684655B2 (ja) *	2002-12-18	2011-05-18	ラボラトワールブザンアンテルナスィヨナル	４−ヒドロキシタモキシフェンによる乳房密度低下
WO2004054557A2 (en) *	2002-12-18	2004-07-01	Laboratoires Besins International	Treatment of mastalgia with 4-hydroxy tamoxifen
US9173836B2 (en)	2003-01-02	2015-11-03	FemmeParma Holding Company, Inc.	Pharmaceutical preparations for treatments of diseases and disorders of the breast
JP2006515026A (ja)	2003-01-02	2006-05-18	フェムファーマホールディングカンパニー，インコーポレイテッド	乳房の疾患および障害の処置のための薬学的調製物
CA2519980C (en)	2003-04-01	2012-04-10	Laboratoires Besins International	Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
US7767717B2 (en) *	2003-06-09	2010-08-03	Ascend Therapeutics, Inc.	Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
PL1694319T3 (pl) *	2003-12-15	2009-01-30	Besins Healthcare Lu Sarl	Zastosowanie 4-hydroksytamoksyfenu do wytwarzania leku do leczenia ginekomastii
US7968532B2 (en) *	2003-12-15	2011-06-28	Besins Healthcare Luxembourg	Treatment of gynecomastia with 4-hydroxy tamoxifen
EP1550440A1 (en) *	2003-12-15	2005-07-06	Laboratoires Besins International	Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia
CN1946387B (zh) *	2004-03-22	2011-08-31	法国法杏大药厂	4-羟基三苯氧胺在制备治疗和预防良性乳房疾病的药物中的应用
EP1579857A1 (en) *	2004-03-22	2005-09-28	Laboratoires Besins International	Chemically stable compositions of 4-hydroxy tamoxifen
US7507769B2 (en) *	2004-03-22	2009-03-24	Laboratoires Besins International	Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1579856A1 (en) *	2004-03-22	2005-09-28	Laboratoires Besins International	Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1647271A1 (en) *	2004-10-14	2006-04-19	Laboratoires Besins International	4-Hydroxy tamoxifen gel formulations
EP1799201B1 (en) *	2004-10-14	2008-11-26	Laboratoires Besins International	4-hydroxy tamoxifen gel formulations
US20070088012A1 (en) *	2005-04-08	2007-04-19	Woun Seo	Method of treating or preventing type-2 diabetes
GEP20125432B (en)	2005-10-12	2012-03-26	Unimed Pharmaceuticals Llc	Improved testosterone gel and use thereof
KR100850910B1 (ko) *	2006-12-22	2008-08-07	삼성전자주식회사	블루투스 디바이스를 연결하기 위한 장치 및 방법
US20080153789A1 (en) *	2006-12-26	2008-06-26	Femmepharma Holding Company, Inc.	Topical administration of danazol
US20110003000A1 (en) *	2009-07-06	2011-01-06	Femmepharma Holding Company, Inc.	Transvaginal Delivery of Drugs
AU2017312499B2 (en)	2016-08-19	2023-02-02	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2860900D1 (en) *	1977-08-22	1981-11-05	Ici Plc	Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
DE3046719C2 (de) *	1980-12-11	1983-02-17	Klinge Pharma GmbH, 8000 München	1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
FR2515041A1 (fr)	1981-10-26	1983-04-29	Besins Jean	Medicament a base de progesterone pour le traitement des affections mammaires

1984
- 1984-01-20 FR FR8400927A patent/FR2558373B1/fr not_active Expired
- 1984-12-19 EP EP84201920A patent/EP0151326B1/fr not_active Expired
- 1984-12-21 EP EP85900469A patent/EP0169214B1/fr not_active Expired - Lifetime
- 1984-12-21 US US06/777,786 patent/US4919937A/en not_active Expired - Lifetime
- 1984-12-21 AT AT85900469T patent/ATE73334T1/de not_active IP Right Cessation
- 1984-12-21 WO PCT/EP1984/000436 patent/WO1985003228A1/fr not_active Ceased
- 1984-12-21 JP JP60500495A patent/JPH0667826B2/ja not_active Expired - Fee Related
- 1984-12-21 DE DE8585900469T patent/DE3485581D1/de not_active Expired - Lifetime
1985
- 1985-09-17 DK DK420385A patent/DK155143C/da active

Also Published As

Publication number	Publication date
EP0169214A1 (fr)	1986-01-29
EP0151326B1 (fr)	1989-07-12
DK155143C (da)	1989-07-03
EP0169214B1 (fr)	1992-03-11
FR2558373A1 (fr)	1985-07-26
ATE73334T1 (de)	1992-03-15
FR2558373B1 (fr)	1987-07-03
JPH0667826B2 (ja)	1994-08-31
US4919937A (en)	1990-04-24
WO1985003228A1 (fr)	1985-08-01
DK155143B (da)	1989-02-20
EP0151326A1 (fr)	1985-08-14
DE3485581D1 (de)	1992-04-16
DK420385D0 (da)	1985-09-17
JPS61500914A (ja)	1986-05-08

Publication	Publication Date	Title
DK420385D0 (da)	1985-09-17	Antioestrogent laegemiddel til perkutan indgift
ATE17079T1 (de)	1986-01-15	Praeparat zur behandlung von wunden der hautoberflaeche und verfahren zur herstellung des praeparats.
DE3684190D1 (de)	1992-04-16	Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
DE69132688D1 (de)	2001-09-20	Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
ATE230985T1 (de)	2003-02-15	Verwendung von xanthophyllen zur herstellung von arzneimitteln zur verbesserung der muskel- funktionsdauer oder zur behandlung von muskelstörungen oder erkrankungen
ATE319474T1 (de)	2006-03-15	Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
IS1565B (is)	1994-12-13	Aðferð við framleiðslu á N1-súbstitúeruðum bensimidasólafleiðum til að nota við lækningar
ATE219363T1 (de)	2002-07-15	Lösliche prodrugs von paclitaxel
JPS5756427A (en)	1982-04-05	Medicine containing 2-phenyl-1,2-benzisoselenazole- 3(2h)-one
DE3582439D1 (de)	1991-05-16	Mittel zur behandlung von herzerkrankungen.
SE9301290D0 (sv)	1993-04-20	Anvaendning av en somatostatinanalog
DE69426334D1 (de)	2000-12-28	Parenterales Busulfan zur Behandlung von malignen Krankheiten
NO166939C (no)	1991-09-18	Analogifremgangsmaate for fremstilling av terapeutisk aktive carboxylsyrederivater.
US4678668A (en)	1987-07-07	Method of reducing soft tissue swelling and pain
IT1170214B (it)	1987-06-03	Composizione farmaceutica per la cura delle arteriopatie periferiche
SE7902742L (sv)	1979-09-29	Disubstituerade 3-cefem-4-karboxylsyraderivat samt forfarande for framstellning derav
FR2731907B1 (fr)	1997-06-20	Composition dermatologique et/ou cosmetique depigmentante et utilisation dans une methode cosmetique
JPS57122085A (en)	1982-07-29	Circulatory disease extirpenter and use
SE9801647D0 (sv)	1998-05-12	Therapeutic composition
FR2439194A1 (fr)	1980-05-16	Derives de la dibenzothiepine, leur procede de preparation et leur application therapeutique
ATE223721T1 (de)	2002-09-15	Edelfosin zur behandlung von hirntumoren
BR8008818A (pt)	1981-06-23	Peptidos farmacologicamente ativos e medicamentos contendo os mesmos
ES2006121A6 (es)	1989-04-01	Procedimiento para la preparacion de una composicion farmaceutica destinada al tratamiento de enfermedades cutaneas.
DE59108104D1 (de)	1996-09-26	Arzneimittel enthaltend cd14
KR880002535A (ko)	1988-05-09	약제로서의 15-데옥시스퍼구알린의 용도